Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy

Ye Chen

doi:10.54097/kxkp0d23

Authors

Ye Chen

DOI:

https://doi.org/10.54097/kxkp0d23

Keywords:

Cancer, vitamin C, ascorbyl palmitate, drug delivery, nanoparticles.

Abstract

Cancer treatment continues to face formidable challenges, including the side effects associated with traditional treatment methods, cancer cell resistance, and the lack of specificity in existing therapeutic drugs. The anticancer properties of ascorbic acid (AA) offer new hope for cancer treatment. As a derivative of AA, ascorbyl palmitate (AP) inherits the antioxidative properties of AA and is even more stable. Additionally, AP's amphiphilic nature allows it to be utilized as a nanoliposome. This paper summarizes various modification approaches of AP within drug delivery platforms, revealing its promising role in cancer therapy. Specifically, AP can be employed to modify liposomes, enhancing the targeting and stability of existing cancer drugs while reducing their toxicity. Additionally, AP is thought to have the potential to function as a cancer vaccine platform. Despite its limitations, using AP to treat cancer offers a novel viewpoint on cutting-edge therapeutic approaches and propels the development of current therapeutic methods.

Downloads

Download data is not yet available.

References

Reang J, et al. Understanding the therapeutic potential of ascorbic acid in the battle to overcome cancer. Biomolecules. 2021;11(8):1130.

Ferlay J, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020 (https://gco.iarc.fr/today, accessed February 2021).

German-Cortés J, et al. Solid lipid nanoparticles: Multitasking nano-carriers for cancer treatment. Pharmaceutics. 2023;15(3):831.

Yang Y, et al. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy. European Journal of Pharmaceutical Sciences. 2017;105:219–29.

Mishra DK, et al. Lipid based nanocarriers: A translational perspective. Nanomedicine: Nanotechnology, Biology and Medicine. 2018;14(7):2023–50.

Capecchi E, et al. Biosynthesis of novel ascorbic acid esters and their encapsulation in lignin nanoparticles as carriers and Stabilizing Systems. International Journal of Molecular Sciences. 2023;24(10):9044.

Sawant RR, et al. Palmitoyl ascorbate liposomes and free ascorbic acid: Comparison of anticancer therapeutic effects upon Parenteral Administration. Pharmaceutical Research. 2011;29(2):375–83.

Palma S, et al. Solubilization of hydrophobic drugs in octanoyl‐6‐o‐ascorbic acid micellar dispersions. Journal of Pharmaceutical Sciences. 2002;91(8):1810–6.

Asada R, et al. Carcinostatic effects of diverse ascorbate derivatives in comparison with aliphatic chain moiety structures: Promotion by combined hyperthermia and reduced cytotoxicity to normal cells. Oncology Letters. 2012;3(5):1042–6.

Palma S, et al. Nanostructures from alkyl vitamin C derivatives (ASCN): Properties and potential platform for Drug Delivery. International Journal of Pharmaceutics. 2007;345(1–2):26–34. -

Benedini L, et al. The ascorbyl palmitate-water system: Phase diagram and State of Water. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2011;375(1–3):178–85.

Sánchez Vallecillo MF, et al. A liquid crystal of ascorbyl palmitate, used as vaccine platform, provides sustained release of antigen and has intrinsic pro-inflammatory and adjuvant activities which are dependent on MyD88 adaptor protein. Journal of Controlled Release. 2015;214:12–22.

Gopinath D, et al. Ascorbyl palmitate vesicles (aspasomes): Formation, characterization and applications. International Journal of Pharmaceutics. 2004;271(1–2):95–113.

Caritá AC, et al. Vitamin C: One compound, several uses. advances for delivery, efficiency and stability. Nanomedicine: Nanotechnology, Biology and Medicine. 2020;24:102117.

Cameron E, et al. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences. 1976;73(10):3685–9.

Sawant RR, et al. Palmitoyl ascorbate-loaded polymeric micelles: Cancer cell targeting and cytotoxicity. Pharmaceutical Research. 2010;28(2):301–8.

Zhou M, et al. Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoural therapy. Drug Delivery. 2017;24(1):1230–42.

Li J, et al. Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumour efficacy. Scientific Reports. 2016;6(1).

Schwendener RA. Liposomes as vaccine delivery systems: A review of the recent advances. Therapeutic Advances in Vaccines. 2014;2(6):159–82.

Chen XJ, et al. Ascorbyl palmitate application in preparing antitumour drug[P]. China: CN106138036A, 2016.

Wu J. The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application. Journal of Personalized Medicine. 2021;11(8):771.

Shimpo K, et al. Ascorbic acid and adriamycin toxicity. The American Journal of Clinical Nutrition. 1991;54(6).

Weaver BA. How taxol/Paclitaxel kills cancer cells. Molecular Biology of the Cell. 2014;25(18):2677–81.

Hercberg S, et al. The SU.VI.MAX study. Archives of Internal Medicine. 2004;164(21):2335.

Padayatty SJ, et al. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Annals of Internal Medicine. 2004;140(7):533.